-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3604 Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Hematology Disease Topics & Pathways:
Research, Biological therapies, adult, Clinical Practice (Health Services and Quality), Bone Marrow Failure Syndromes, elderly, Clinical Research, health outcomes research, Diseases, Immune Disorders, real-world evidence, Therapies, registries, Lymphoid Malignancies, Adverse Events, Myeloid Malignancies, Study Population, Human, Transplantation
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Imran Ahmad, MD1, Samia Harbi, MD2*, Raynier Devillier, MD, PhD2*, Cristina Castilla-Llorente, MD3*, Marie Robin, MD, PhD4*, Micha Srour5*, Jacques-Olivier Bay, MD, PhD6*, Patrice Ceballos, MD7*, Stéphanie Nguyen-Quoc, MD, PhD8*, Édouard Forcade9*, Claude-Éric Bulabois, MD10*, Amandine Charbonnier, MD11*, Pascal Turlure, MD12*, Sylvain Chantepie, MD13*, Sébastien Maury14*, Michael Loschi, MD15*, Hélène Labussière-Wallet16*, Tony Marchand, MD, PhD17*, Marianne Schwarz, MD18*, Ambroise Marçais, MD, PhD19*, Ana Berceanu, MD20*, Étienne Daguindau, MD20*, Patrice Chevallier, MD21, Anne Huynh, MD22*, Mohamad Mohty, MD, PhD23, Remy Dulery, MD, PhD24*, Johan Maertens, MD, PhD25*, Xavier Poiré, MD, PhD26*, Natacha Maillard, MD27*, Marie-Thérèse Rubio, MD, PhD28*, Gaëlle Guillerm, MD29*, Yves Chalandon, MD30, Anne-Lise Ménard31* and Jérôme Cornillon, MD32*

1Hôpital Maisonneuve-Rosemont, Hopital Maisonneuve-Rosemont, Montreal, QC, Canada
2Hematology and Transplantation, Institut Paoli-Calmettes, Aix Marseille University, Marseille, France
3Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, France
4Department of Hematology, Transplantation Division, Hopital Saint-Louis, Paris Cedex 10, France
5CHU de Lille, Lille, France
6Service d’hématologie, CHU Clermont-Ferrand, Clermont-Ferrand, France
7Clinical Hematology Department, Montpellier University Hospital, MONTPELLIER, France
8Service d'hématologie clinique, Hôpital de la Pitié-Salpêtrière AP-HP, Paris, France
9Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Pessac, France
10Hématologie Soins Intensifs, CHU Grenoble Alpes, Grenoble, France
11Service d’Hématologie Clinique, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France
12Service d'Hématologie Clinique, CHU de Limoges, Limoges, France
13Institut d'Hématologie, CHU de Caen, Caen, France
14Hematology Department, Hôpitaux universitaires Henri Mondor AP-HP & Université Paris Est Créteil, Créteil, France
15Service d’hématologie, CHU de Nice, Nice, France
16Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
17INSERM U1236, Université Rennes 1, Rennes, France
18Centre Hospitalier Universitaire d’Angers, Angers, France
19Department of Hematology, Institut Imagine, Necker Hospital, Paris Descartes University, Paris, France
20Department of Clinical Hematology, CHU de Besançon, Besançon, France
21Service d'hématologie, CHU de Nantes, Nantes, France
22Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
23Saint-Antoine Hospital, Sorbonne University, Paris, France
24INSERM UMRs 938, Sorbonne University, Centre de Recherche Saint-Antoine (CRSA), Paris, France
25Department of Hematology, University Hospitals Leuven, Leuven, Belgium
26Section of hematology, Institut Roi Albert II, Cliniques Universitaires St-Luc, Brussels, Belgium
27Hematology Department, CHU de Poitiers, Poitiers, France
28Department of Hematology, Centre Hospitalier Régional Universitaire (CHRU), Vandoeuvre-les-Nancy, France
29Service d'hématologie, Hôpital Morvan, CHRU Brest, Brest, France
30Univ. Hospital of Geneva, Geneva, Switzerland
31Département d'hématologie clinique, Centre Henri-Becquerel, Rouen, France
32Département d’hématologie clinique et de thérapie cellulaire, CHU de St-Étienne, Saint-Étienne, France


Higher patient age is no longer considered to be a barrier for allogeneic hematopoietic cell transplantation (HCT). We sought to study the impact of different types of donors on the outcomes of HCT in subjects aged 65 years (y) or more, and to evaluate the determinants of these outcomes.


SFGM-TC registry data on first HCTs performed between January 2013 and July 2021 in patients aged 65 y or more, with myeloablative or reduced-intensity conditioning, and a 10/10 human leukocyte antigen (HLA) matched sibling donor (MSD), matched unrelated donor (MUD) or haploidentical donor (HAP) were analyzed. Main exclusion criteria were: MSD/MUD-HCT performed without anti-T lymphocyte globulin (ATG), and HAP-HCT performed without post-transplant cyclophosphamide (PTCY). Univariate analyses according to donor type, as well as multivariable analyses were performed.


A total of 1176 patients met the eligibility criteria (215 MSD, 721 MUD, 240 HAP). Median follow-up was 2.8 y. In univariate analysis, there was no difference between donor types in terms of 3-y overall survival (OS: MSD 50%, MUD 49%, HAP 49%, p=0.52), progression-free survival (PFS: MSD 41%, MUD 45%, HAP 44%, p=0.51) and graft-versus-host disease-free, relapse-free survival (GRFS: MSD 34%, MUD 32%, HAP 35%, p=0.67). With MSD, the cumulative incidence of progression at 3 y was significantly higher at 47% (MUD 29%, HAP 29%, p<0.001), and non-relapse mortality (NRM) significantly lower at 12% (MUD 26%, HAP 27%, p<0.001). These MSD results were confirmed in multivariable analysis. Incidence of acute graft-versus-host disease (GVHD) at 180 days was lower with MSD: grades II-IV 21% (MUD 35%, HAP 38%, p<0.001) and grade III-IV 8% (MUD 13%, HAP 15%, p=0.05). Incidence of chronic GVHD at 2 y was comparable between MSD, MUD and HAP transplants: moderate to severe 14%, 18% and 15%, respectively, and severe 5%, 6% and 5%, respectively.


In patients aged 65 y or more, MSD/MUD HCT performed with ATG and HAP HCT performed with PTCY yielded similar survival outcomes. MSD HCT is associated with a lower acute GVHD and NRM but a higher relapse risk. Reducing the toxicity of MUD and HAP HCT may yield better results than with MSD HCT in this population.

Acknowledgements: Nicole Raus, Data manager coordinator, SFGM-TC. Viviane Fossat, Secretary, SFGM-TC.

Disclosures: Ahmad: Novartis, InCyte, Abbvie, Medexus, Jazz, Sanofi: Consultancy, Honoraria. Devillier: Astellas: Honoraria; Incyte: Honoraria; Jazz Pharmaceuticals: Honoraria; Medac: Honoraria; Sanofi: Honoraria; MSD: Honoraria. Castilla-Llorente: Gilead/Kite: Consultancy, Other: Travel support; Nektar Therapeutics: Consultancy. Forcade: Jazz: Other: Travel support; Gilead Sciences: Other: Travel support, Speakers Bureau; GSK: Speakers Bureau; Alexion: Other: Travel support, Speakers Bureau; Sanofi: Speakers Bureau; MSD: Other: Travel support; Novartis: Consultancy, Other: Travel support, Speakers Bureau; Astellas: Speakers Bureau. Bulabois: ASTELLAS: Speakers Bureau; BMS: Consultancy. Loschi: Abbvie: Honoraria; Alexion: Honoraria; Astra Zeneca: Honoraria; BMS Celgene: Honoraria; Gilead: Honoraria; GSK: Honoraria; Jazz: Honoraria; Novartis: Honoraria; Pfizer: Honoraria; Sanofi: Honoraria; Sobi: Honoraria; Takeda: Honoraria. Marchand: SERVIER: Consultancy, Honoraria; JAZZ PHARMACEUTICALS: Consultancy, Honoraria; SOBI: Consultancy; ASTELLAS: Consultancy. Chevallier: Sanofi: Honoraria; Mallinckrodt Pharmaceuticals: Honoraria; Takeda: Honoraria; Incyte: Honoraria, Research Funding; Immedica Pharma: Honoraria; Servier: Honoraria. Huynh: Pfizer: Other: advisory board; Medac: Other: Advisory board; Astellas: Other: Advisory board; Servier: Other: Advisory board; Jazz: Other: travel fees, advisory board; Novartis: Other: travel fees, advisory board; Neovii: Other: Advisory board. Mohty: JAZZ PHARMACEUTICALS: Honoraria, Research Funding. Dulery: Novartis: Honoraria; Arthur Sachs Scholarships: Research Funding; Servier Foundation: Research Funding; Monahan Foundation: Research Funding; Philippe Foundation: Research Funding; DPC AP-HP: Research Funding; Takeda: Honoraria; Kite Pharma / Gilead: Other: Registration fees for scientific meetings and travel accommodations ; Ligue Nationale contre le Cancer: Research Funding. Chalandon: MSD: Honoraria, Other: travel support; Sanofi: Other: travel support; Abbvie: Honoraria, Other: travel support; Janssen: Other: travel support; Gilead: Honoraria, Other: travel support; Astra-Zeneca: Honoraria, Other: travel support; Servier: Honoraria; Amgen: Honoraria, Other: travel support; Novartis: Honoraria, Other: travel support; Pfizer: Honoraria; BMS: Honoraria, Other: travel support; Jazz: Honoraria, Other: travel support, Speakers Bureau; Roche: Honoraria, Other: travel support; Incyte: Honoraria, Other: travel support.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH